Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Continued Democratization of Personalized Healthcare

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at home a few short years ago, but the experience taught millions of people a valuable lesson: personalized healthcare is essential and should be a part of the healthcare journey moving forward.

Technology is leading the way in democratizing personalized healthcare. Wearable technology, from fitness monitoring to biosensors, can give patients and providers valuable health information and provide new tools for improving health outcomes. Advanced data gathering creates health equity for everyone.

David Kemp, host of Highway to Health, spoke with two women working on the front lines of that personalized healthcare mission. Sherlock Biosciences’ Julie Garlikov, Chief Commercial Officer, and Karen Davies, Chief Development Officer, gave Kemp a window into the science behind molecular diagnostics, which is changing the game of testing to a more democratized and decentralized approach to personalized healthcare.

What types of testing does Sherlock Biosciences do?

“We’re a pre-commercial company looking at the intersection of our chemistries and technologies and where our tests perform the best,” Garlikov said. “And then we talked with many consumers to understand where they want to test and what they want to test for at home. And when we put those two together, the intersection is in the areas of respiratory and sexual health. And when I say respiratory, I’m not just talking COVID tests. I’m talking about flu, or RSV, or even, in the future, strep throat, or walking pneumonia.”

Kemp’s conversation with Garlikov and Davies includes the following:

  • Creating efficiencies through at-home testing
  • The advancing technologies creating these new testing solutions
  • The importance of advanced diagnostics for rural and underserved communities

“Accessibility is the big thing,” Davies said. “And portability. A small, easy-to-run test; you can stick it in your backpack, you can stick it in your suitcase, or you can mail order it if you live in a remote region. If I’ve got that test in my backpack or I’ve got that test at home, I can run it. It’s negative most of the time. And so I can provide self-care. If it’s positive, I know it’s worth the trip to see my doctor.”

About Karen

Karen Davies is a mechanical engineer with a BS from Stanford University. Her twenty-plus-year career in medical devices includes product development, technical leadership, program management, quality and regulatory compliance, and strategic planning. She is a sought-out mentor by personnel in multiple functional areas, including Instrumentation, Assay Development, and Marketing.

About Julie

Julie Garlikov is a full-stack, omnichannel, B2C/B2B marketing & commercialization executive with numerous successes in accelerating growth for digital consumer healthcare and health, wellness & beauty (skincare, vitamins, nutrition), and beverage brands. Her passion lies in building and scaling brands to take them to the next level. Garlikov holds an MBA in marketing from Columbia Business School and a BA from the University of California, Berkeley.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512